Efficacy of Dexamethasone to Improve Clinical Outcomes in Coronary Artery Bypass Patients
Status:
Completed
Trial end date:
2019-03-31
Target enrollment:
Participant gender:
Summary
This is a single-center, double-blind, randomized controlled clinical trial comparing four
groups: placebo conventional coronary artery bypass graft (CCABG) group, dexamethasone CCABG
group, placebo off-pump coronary artery bypass (OPCAB) group, and dexamethasone OPCAB group.
The primary outcomes of this study is comprised of presence of arrhythmia, major adverse
cardiac events (MACE), myocardial infarction, stroke, renal failure, respiratory failure,
inflammation, and death. These primary outcomes were assessed during the surgery, 18 hours
post surgery, every day during the hospital stay, 14 days and 30 days post surgery.